Dr. Amit Sachdev, M.D., MS
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Michigan State University College of Human Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 170
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Michigan State University College of Human Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MI license 4301104719
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Edward W Sparrow Hospital Lansing, MI
- Mclaren Greater Lansing Lansing, MI
Medical groups
- Msu Health Care Inc. (198 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 170
- Services billed
- 7,353
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 57 | 56 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 43 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 29 | 25 |
| Established patient office or other outpatient visit, 40-54 minutes | 28 | 24 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 23 | 20 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in East Lansing, MI | 143 |
| Pyridostigmine Bromide Other prescribers in East Lansing, MI | 118 |
| Prednisone Other prescribers in East Lansing, MI | 102 |
| Gammaplex (immun glob g(igg)/gly/iga 0-50) | 79 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 73 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 68 |
| Duloxetine Hcl Other prescribers in East Lansing, MI | 58 |
| Pregabalin Other prescribers in East Lansing, MI | 49 |
| Soliris (eculizumab) | 47 |
| Mycophenolate Mofetil Other prescribers in East Lansing, MI | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 36 companies reported 187 payments worth $146,935 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $38,893 |
|---|---|
| Argenx US, Inc. | $38,838 |
| Amgen Inc. | $28,262 |
| UCB, Inc. | $18,378 |
| Genzyme Corporation | $16,269 |
| Csl Behring | $4,359 |
| Catalyst Pharmaceuticals, Inc. | $293 |
| Janssen Biotech, Inc. | $211 |
| Compensation for services other than consulting (speaking, faculty) | $102,762 |
|---|---|
| Consulting Fee | $27,639 |
| Travel and Lodging | $12,257 |
| Food and Beverage | $4,188 |
| Education | $88.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Dec 6, 2025 | Consulting Fee | $11,203 |
| Argenx US, Inc. Jan 14, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $7,500 |
| Alexion Pharmaceuticals, Inc. Mar 13, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $6,860 |
| Argenx US, Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $6,000 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,900 |
| Argenx US, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $4,500 |
| UCB, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,351 |
| Amgen Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,678 |
| Alexion Pharmaceuticals, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,540 |
All 90 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,000 |
| Amgen Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,065 |
| UCB, Inc. Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $1,300 |
| Amgen Inc. Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,065 |
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $2,146 |
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,686 |
| Janssen Biotech, Inc. Dec 9, 2025 | Education in-kind | $76.99 |
| Genzyme Corporation Dec 6, 2025 | Consulting Fee | $11,203 |
| Genzyme Corporation Dec 6, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $577 |
| Alexion Pharmaceuticals, Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| Amgen Inc. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,759 |
| Amgen Inc. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,759 |
| Amgen Inc. Nov 25, 2025 | Travel and Lodging travel to SYRACUSE, NY · in-kind | $713 |
| Amgen Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,065 |
| Alexion Pharmaceuticals, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,540 |
| Argenx US, Inc. Nov 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Mishawaka, IN | $683 |
| Amgen Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,065 |
| Alexion Pharmaceuticals, Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,950 |
| Alexion Pharmaceuticals, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| Alexion Pharmaceuticals, Inc. Nov 5, 2025 | Travel and Lodging travel to Kalamazoo, MI · in-kind Company’s descriptionSpeaker Expenses | $592 |
| Alexion Pharmaceuticals, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| Genzyme Corporation Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,351 |
| UCB, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $1,300 |
| Amgen Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,678 |
| UCB, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $1,300 |
| Amgen Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $613 |
| Amgen Inc. Oct 22, 2025 | Travel and Lodging travel to West Bloomfield, MI · in-kind | $807 |
| Alexion Pharmaceuticals, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,540 |
| Alexion Pharmaceuticals, Inc. Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $1,770 |
| UCB, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $200 |
| UCB, Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $1,300 |
| Argenx US, Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $6,000 |
| Argenx US, Inc. Sep 2, 2025 | Travel and Lodging VYVGART · Immunology · travel to Omaha, NE | $296 |
| Amgen Inc. Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $613 |
| Argenx US, Inc. Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| Argenx US, Inc. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $1,500 |
| Argenx US, Inc. Jul 24, 2025 | Travel and Lodging VYVGART · Immunology · travel to Traverse City, MI | $890 |
| Argenx US, Inc. Jul 24, 2025 | Travel and Lodging VYVGART · Immunology · travel to Traverse City, MI | $15.00 |
| Argenx US, Inc. Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,250 |
| Argenx US, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,470 |
| Argenx US, Inc. Jun 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Omaha, NE | $597 |
| Argenx US, Inc. Jun 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Omaha, NE | $310 |
| Argenx US, Inc. Jun 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Omaha, NE | $55.00 |
| Argenx US, Inc. Jun 12, 2025 | Travel and Lodging VYVGART · Immunology · travel to WYANDOTTE, MI | $1,044 |
| Argenx US, Inc. Jun 12, 2025 | Travel and Lodging VYVGART · Immunology · travel to WYANDOTTE, MI | $15.00 |
| Argenx US, Inc. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $750 |
| UCB, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
| UCB, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $1,300 |
| UCB, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $1,300 |
| UCB, Inc. May 28, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Saginaw, MI · in-kind | $135 |
| Alexion Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $2,450 |
| Alexion Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $2,450 |
| Csl Behring May 16, 2025 | Consulting Fee Hizentra · Immunology | $2,970 |
| Csl Behring May 16, 2025 | Travel and Lodging Hizentra · Immunology · travel to San Diego, CA | $489 |
| Csl Behring May 16, 2025 | Travel and Lodging Hizentra · Immunology · travel to San Diego, CA | $58.10 |
| Csl Behring May 16, 2025 | Travel and Lodging Hizentra · Immunology · travel to San Diego, CA | $48.00 |
| Csl Behring May 16, 2025 | Travel and Lodging Hizentra · Immunology · travel to San Diego, CA | $24.94 |
| Csl Behring May 14, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Argenx US, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $4,500 |
| Argenx US, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,250 |
| Argenx US, Inc. Apr 25, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $68.25 |
| Argenx US, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $1,500 |
| UCB, Inc. Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $1,300 |
| UCB, Inc. Apr 8, 2025 | Consulting Fee | $2,600 |
| Csl Behring Apr 4, 2025 | Travel and Lodging Haegarda · Immunology · travel to San Diego, CA · in-kind | $300 |
| Csl Behring Apr 4, 2025 | Travel and Lodging Haegarda · Immunology · travel to San Diego, CA · in-kind | $258 |
| UCB, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $1,300 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
| Argenx US, Inc. Mar 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $697 |
| Argenx US, Inc. Mar 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $445 |
| Argenx US, Inc. Mar 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $421 |
| Argenx US, Inc. Mar 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $159 |
| Argenx US, Inc. Mar 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Albany, NY | $85.00 |
| Alexion Pharmaceuticals, Inc. Mar 13, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $6,860 |
| Alexion Pharmaceuticals, Inc. Mar 1, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Detroit, MI Company’s descriptionConsulting Expenses | $58.10 |
| Alexion Pharmaceuticals, Inc. Mar 1, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Philadelphia, PA Company’s descriptionConsulting Expenses | $48.98 |
| Alexion Pharmaceuticals, Inc. Mar 1, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Detroit, MI Company’s descriptionConsulting Expenses | $32.00 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $325 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,900 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Philadelphia, PA · in-kind Company’s descriptionConsulting Expenses | $1,034 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Detroit, MI Company’s descriptionConsulting Expenses | $58.10 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Philadelphia, PA Company’s descriptionConsulting Expenses | $38.94 |
| Alexion Pharmaceuticals, Inc. Feb 8, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Detroit, MI | $115 |
| Alexion Pharmaceuticals, Inc. Feb 8, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Detroit, MI | $23.00 |
| Alexion Pharmaceuticals, Inc. Feb 7, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Nashville, TN · in-kind Company’s descriptionSpeaker Expenses | $375 |
| Argenx US, Inc. Jan 14, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $7,500 |
| Argenx US, Inc. Jan 14, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Lakewood, CO | $275 |
| UCB, Inc. Jan 7, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Savannah, GA · in-kind | $54.94 |
| UCB, Inc. Jan 7, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Savannah, GA · in-kind | $35.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $151,297 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
Argenx US, Inc. - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi US Services Inc. · Active, not recruiting · NCT06290128 - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Recruiting · NCT06290141 - A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. - Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
Alexion Pharmaceuticals, Inc. - A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase
Novartis Pharmaceuticals Corporation - A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in …
Eisai Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.